Increased ammonia levels and its association with visceral obesity and insulin resistance
https://doi.org/10.31146/1682-8658-ecg-169-9-75-79
Abstract
Hyperammonemia is considered as a significant trigger factor in the progression of liver diseases, starting from the stage of steatosis. There is also a link between high levels of ammonia and metabolic syndrome. The article discusses the relationship of hyperammonemia with a violation of carbohydrate metabolism. It is likely that an increase in ammonia is associated with an increase in visceral fat and may be a predictor of the development of insulin resistance as a key factor in carbohydrate metabolism disorders.
About the Authors
G. V. Shavkuta
Rostov State Medical University
Russian Federation
Galina V. Shavkuta, Rostov-on-Don, Russia, Russia
Russian Federation
Galina V. Shavkuta, Rostov-on-Don, Russia, Russia
T. V. Shnyukova
Rostov State Medical University
Russian Federation
Rostov-on-Don, Russia, Russia
Russian Federation
Rostov-on-Don, Russia, Russia
E. S. Kolesnikova
Rostov State Medical University
Russian Federation
Rostov-on-Don, Russia, Russia
Russian Federation
Rostov-on-Don, Russia, Russia
V. V. Kruchinin
Rostov State Medical University
Russian Federation
Rostov-on-Don, Russia, Russia
Russian Federation
Rostov-on-Don, Russia, Russia
A. K. Lyutova
Rostov State Medical University
Russian Federation
Rostov-on-Don, Russia, Russia
Russian Federation
Rostov-on-Don, Russia, Russia
A. S. Timchenko
Rostov State Medical University
Russian Federation
Rostov-on-Don, Russia, Russia
Russian Federation
Rostov-on-Don, Russia, Russia
References
1. Matoori, S., & Leroux, J.-C. (2015). Recent advances in the treatment of hyperammonemia. Advanced Drug Delivery Reviews, 90, 55–68. doi:10.1016/j.addr.2015.04.009
2. Hadjihambi, A., Khetan, V., & Jalan, R. (2014). Pharmacotherapy for hyperammonemia. Expert Opinion on Pharmacotherapy, 15(12), 1685–1695. doi: 10.1517/14656566.2014.931372
3. R.Jalan, F. De Chiara et al. “Ammonia produces hathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension”, Journal of hepatology, 4, vol.64 April 2016, 823–833.
4. Lindquist, J.N., Parsons, C.J., Stefanovic, B., and Brenner D.A. 2004. Regulation of alpha1(I)
5. Ilchenko L. Y., Nikitin I. G. Hyperammonium in patients with precirrhosis stage: clinical reality? The Russian Archives of Internal Medicine. 2018;8(3):186–193. (In Russ.) https://doi.org/10.20514/2226–6704–2018–8–3–186–193
6. De Chiara, F; Habtension, A; Davies, N; Andreola, F; Rombouts, K; Arias, N; Thomsen, KL; De Chiara, F; Habtension, A; Davies, N; Andreola, F; Rombouts, K; Arias, N; Thomsen, KL; Jalan, R; – view fewer (2017). Presented at: International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS.
7. Wang, W., Gu, L., Verkhratsky, A., & Peng, L. (2016). Ammonium Increases TRPC1 Expression Via Cav-1/PTEN/AKT/GSK3β Pathway. Neurochemical Research, 42(3), 762–776. doi:10.1007/s11064–016–2004-z
8. Peacock J. L. Oxford Handbook of Medical Statistics / J. L. Peacock, P. J. Peacock / Oxford University Press, 2011.
Review
For citations:
Shavkuta G.V., Shnyukova T.V., Kolesnikova E.S., Kruchinin V.V., Lyutova A.K., Timchenko A.S. Increased ammonia levels and its association with visceral obesity and insulin resistance. Experimental and Clinical Gastroenterology. 2019;(9):75-79. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-169-9-75-79
Views:
758
Email this article 